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INTRODUCTION
This paper outlines the protocol for a quasi-
experimental study1 to test the implemen-
tation of primary healthcare (PHC)- based 
measurement, advice and treatment for heavy 
drinking and comorbid depression at the 
municipal level in three Latin American coun-
tries, Colombia, Mexico and Peru (Scale- up 
of Prevention and Management of Alcohol 
Use Disorders and Comorbid Depression in 
Latin America (SCALA) study).
Heavy drinking is a cause of considerable 
disability, morbidity and mortality.2 Heavy 
drinking is a causal factor for some communi-
cable diseases (including TB and HIV/AIDS), 
for many non- communicable diseases (NCDs, 
including cancers, cardiovascular diseases 
and gastrointestinal diseases) and for many 
mental and behavioural disorders, including 
depression, dementias and suicide.3 4
In PHC settings, two- fifths of people with 
heavy drinking have depression, with risks 
of incident depression higher for heavier as 
opposed to lighter drinkers.5 In addition to 
its role in the aetiology of depression, heavy 
drinking is associated with worsening the 
depression course, including suicide risk, 
impaired social functioning and impaired 
healthcare utilisation.6
Heavy drinking is also a major contributor to 
global health inequalities, with alcohol- related 
harm aggravated by lower socioeconomic 
status7 and extending beyond the individual 
Strengths and limitations of study
 ► Uses a theory- based approach to tailor clinical ma-
terials and training programmes, creating city- based 
Community Advisory Boards, and user- based user 
panels to ensure that tailoring matches user needs, 
municipal services and coproduction of health.
 ► Tests the added value of embedding and implement-
ing primary healthcare activity within municipal- 
based adoption mechanisms and support systems, 
and community- based communication campaigns.
 ► Has a longer time frame (18 months) than is tradi-
tionally used in implementation studies, to assess 
longer term impacts.
 ► Gives considerable emphasis to process evaluation, 
developing logic models to document the fidelity of 
all implementation strategies, and to identify, the 
drivers and barriers and facilitators to successful 
implementation and scale- up.
 ► Due to municipal- based political and technical 
considerations, we are unable to randomise the 
involved municipal areas. We adopt a quasiexperi-
mental design, optimising comparator municipal ar-
eas for confounding, and by using propensity score 
matching.
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drinker to families, communities, health systems and the 
wider economy. Tackling the multiple individual and soci-
etal level harms caused by heavy drinking is essential for 
achieving global targets of reducing deaths from NCDs 
by 25% between 2010 and 2025,8 more so as risk of expo-
sure to harmful use of alcohol increases with increasing 
socioeconomic status.9 In line with tackling harm due to 
lower socioeconomic status, United Nations Sustainable 
Development Goals include Target 3.5, to strengthen the 
prevention and treatment of harmful use of alcohol, with 
two proposed indicators: coverage of treatment interven-
tions (pharmacological, psychosocial and rehabilitation 
and aftercare services) for harmful use of alcohol; and 
per capita alcohol consumption.10 11
Countries in Latin America have the highest alcohol- 
attributable disease burden after Eastern Europe and 
sub- Saharan Africa, with particularly high risks in alcohol- 
attributable traffic injury including violence.12 The 
burden of alcohol- attributable diseases in Latin America 
lead to marked economic costs, with numerous calls to 
implement effective and cost- effective policies.13
A robust and extensive body of literature demonstrates 
the range of evidence- based strategies that can be imple-
mented to reduce heavy drinking in healthcare settings.14 
Questionnaire- based measurement and brief advice 
programmes delivered in PHC are effective15 and cost- 
effective16 17 in reducing heavy drinking. In addition to brief 
advice, treatment for heavy drinking includes cognitive 
behavioural therapy and pharmacotherapy, both of which 
are found to be effective in reducing heavy drinking.18 
Were the proportion of eligible patients receiving advice 
and treatment for heavy drinking to increase to 30% of 
eligible patients, the prevalence of harmful use of alcohol 
could decrease by between 10% and 15% across OECD 
(Organisation for Economic Co- operation) and member 
countries.19 However, to date, measurement and brief 
advice and treatment programmes have failed to achieve 
widespread take- up.19
Two systematic reviews20 21 and two multicountry 
studies22–24 have demonstrated that the proportion of 
PHC patients whose alcohol consumption is measured, 
and of heavy drinking patients given advice can be 
increased by providing training and support to PHC 
providers, although from very low baseline levels, and 
with effects not generally sustained over the longer term. 
Moreover, while there has been some previous research 
in countries of Latin America,25–30 most implementation 
work to date has been undertaken in high- income coun-
tries. The SCALA study will build on previous evidence31 
to fast- track scale- up research and practice in Latin Amer-
ican PHC settings.
Out of a range of implementation frameworks that 
include a sequential approach for scale- up, and that 
provide practical guidance for how to work with organ-
isations, health systems and communities to implement 
and scale- up best practices,32–39 we adopt the Institute for 
Healthcare Improvement’s Framework for going to Full 
Scale, which identifies adoption mechanisms and support 
systems for use across sequential steps, and describes the 
implementation methods that can be used at each step.40
SCALA seeks to address three specific barriers to 
sustained implementation of PHC- based measurement, 
advice and treatment for heavy drinking. The first barrier 
recognises that most PHC- based programmes focus on 
providers alone, whereas successful implementation 
of health interventions within complex health system 
demands addressing a range of underlying structural 
and support systems.40 Phase IV of the WHO study on 
the identification and management of alcohol- related 
problems in primary care concluded that embedding 
PHC- based measurement and brief advice programmes 
within the frame of supportive community and munic-
ipal environments might lead to improved outcomes,41 
although this has never been formally evaluated. Similar 
conclusions were reached by the European Optimising 
Delivery of Healthcare Interventions (ODHIN) study42 
and the US- based Substance Abuse and Mental Health 
Services Administration Screening, Brief Intervention 
and Referral to Treatment initiative.43–45
The second barrier is that standard cut- off points 
for the frequently used alcohol measurement instru-
ment, Alcohol Use Disorders Identification Test, 3- item 
consumption version (AUDIT- C)46 (commonly a score of 
five for both men and women, or five for men and four 
for women) to trigger advice are too low,47 being equiv-
alent to an average daily alcohol consumption of about 
20 g of alcohol (around two standard drinks) or less.48 
Practitioners may well find it problematic to give advice 
at such levels, which would also have huge time implica-
tions, with one in three or four patients being eligible 
for advice in many countries, under this criterion.24 49 
We have argued to adopt similar models to blood pres-
sure, where cut- off points for managing raised blood 
pressure are often determined by levels of blood pressure 
at which treatment has shown to be effective.50 51 Simi-
larly, cut- off points for brief advice could be the baseline 
levels of alcohol consumption found in the randomised 
controlled trials that have investigated the effectiveness 
of PHC- delivered brief advice. In the first Cochrane 
review of the topic that focused on PHC, mean baseline 
levels were 313 g of alcohol per week,52 equivalent to an 
AUDIT- C cut- off of 8.48
The third and final barrier concerns the cost of 
implementing measurement and brief- advice for heavy 
drinking in PHC setting. Although, alcohol advice and 
treatment programmes can lead to substantial reduc-
tions in healthcare costs,16 freeing considerable numbers 
of working age people from alcohol- related diseases,19 
their initial implementation can require a significant 
time- commitment on the part of providers, in terms of 
both initial training requirements and the time taken 
to deliver advice in routine practice. The largest part of 
the costs of implementing measurement and brief advice 
for heavy drinking in PHC settings are directly caused 
by the time spent by the healthcare providers delivering 
this intervention.53 Moreover, this large amount of time 
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is experienced by healthcare providers as an important 
barrier to deliver routine measurement and brief advice 
to their patients.54 As evidence suggests that shorter 
sessions of brief advice are not less effective compared 
with longer sessions,52 55 56 it seems that reducing the time 
spent by healthcare professionals in preparing for these 
sessions could be a viable strategy to increase the overall 
adoption and implementation of alcohol measurement 
and brief advice at PHC level.
Given the strong comorbidity between heavy drinking 
and depression, our protocol includes screening 
for depression for those patients identified as heavy 
drinkers, with appropriate referral or PHC support for 
treatment.57–59
In the SCALA study, we implement three interventions 
(independent variables) for the PHCU:
1. Intensity of clinical package and training (standard, vs 
short, vs none).
2. Training of providers (present, vs absent).
3. Community integration and support (municipal ac-
tion present, vs absent).
The main outcome (dependent variable) is the cumula-
tive proportion of the adult (aged 18+ years) population 
registered with the PHCU that has their alcohol consump-
tion measured within the 18- month implementation test 
period (defined as coverage). Three hypotheses are to be 
tested.
Hypothesis 1
Municipal action leads to more sustainable coverage. 
After 18 months, the difference in coverage between 
municipal action present and municipal action absent for 
those PHCU that receive training is larger than after 12 
months.
Hypothesis 2
In the absence of municipal action, PHCU that have 
received training obtain higher coverage than PHCU that 
do not receive training.
Hypothesis 3
In the presence of municipal action, the short clinical 
package and short training do not lead to less measure-
ment coverage than the standard clinical package and 
standard training.
METHODS AND ANALYSIS
The study is a quasiexperimental design,1 comparing 
changes in measurement and assessment for alcohol 
consumption and comorbid depression, and, if needed, 
advice and/or referral for treatment between PHCUs 
in intervention municipal areas and PHCUs in similar 
control municipal areas. In 2017, prior to a grant applica-
tion, we published a preprotocol for a three- country study 
to test the scale- up of PHC- based programmes to identify 
and manage the harmful use of alcohol and comorbid 
depression.60 Since the application, and during the grant 
negotiation and planning phase, the design of the study 
has changed considerably, essentially moving from a 
two- arm design to a four- arm design, and changing the 
primary outcome measure to the proportion of the adult 
population registered with a PHCU that has their alcohol 
consumption measured, online supplementary file S1, 
online supplementary box S1. With all changes approved 
by the concerned ethics committee, this paper outlines 
the final protocol for a quasiexperimental study to test the 
implementation of PHC- based measurement, advice and 
treatment for heavy drinking and comorbid depression at 
the community level in three Latin American countries, 
Colombia, Mexico and Peru (SCALA study).
Intervention municipal areas are investigator- selected 
from Bogotá (Colombia), Mexico City (Mexico) and 
Callao—Lima (Peru). Control municipal areas are 
investigator- selected in the same cities, on the basis of 
comparability with the intervention municipal area in 
terms of socioeconomic and other characteristics which 
impact on drinking, healthcare and survival, compa-
rable community mental health services and sufficient 
geographical separation to minimise spill over effects 
from the intervention municipal area. Randomised 
selection of the municipal areas was not feasible due to 
organisational limitations. Municipal areas are chosen as 
a scalable implementation unit at mesosystem level that 
can be replicated as the intervention is scaled- up,40 given 
their jurisdictional responsibilities for prevention and 
healthcare services.
Within each intervention municipal area, a local 
Community Advisory Board (CAB) is created of key stake-
holders, including representatives of local and regional 
government, directors of PHC services, non- governmental 
organisations active in providing counselling and treat-
ment services for alcohol and mental health, academic 
experts and local media. The CABs meet regularly during 
the course of the study, giving advice on tailoring mate-
rials for local use, giving advice on adoption mecha-
nisms, support systems and communication campaigns to 
support the action and preparing for sustainability and 
scale- up at the end of the action.
The units of allocation and analysis, that is, study partic-
ipants, are 54 PHCUs and the providers working in them. 
Within each PHCU, eligible providers include any fully 
trained healthcare provider working in the PHCU and 
involved in medical and/or preventive care. Within each 
PHCU, individual providers decide themselves whether 
or not to participate in the study; those who do sign an 
informed consent for their participation. Based on the 
five- country ODHIN study, we estimate that approximately 
two- fifths of providers will consent to join the study.61 The 
overall study design is summarised in figure 1. Fifty- four 
PHCU are invited to join the study until 27 are achieved 
within each of the two municipal areas (intervention and 
control) across the three countries (nine per municipal 
area within each of the three countries).
Within each intervention municipal area, a user panel 
(UP) is created of providers and patients drawn from 
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the PHC centres to advise on the tailoring of patient and 
provider materials and on provider training programmes.
For the first 6 months of the 18- month implementation 
and test period, a four- arm design is adopted, figure 2. 
Within the comparator municipal area, 12 PHCUs out of 
the 27 are randomly allocated to control (Arm 1), and 
15 are allocated to receive short training to implement a 
short clinical package (Arm 2). Within the intervention 
municipal area, in which all 27 PHCU receive municipal 
action, 15 PHCUs are randomly allocated to receive short 
training to implement a short clinical package (Arm 3), 
and 12 PHCUs are allocated to receive standard training 
to implement a standard clinical package (Arm 4). 
Random allocation was undertaken using Excel random 
number generator.
The clinical package comprises measurement instru-
ments, patient information and advice material and 
provider guidance material, with the differences between 
Figure 2 Study design for the first 6 months of the 18- month implementation period.PHCU, primary healthcare units.
Figure 1 Study flow diagram.
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the standard and short clinical materials are described 
in online supplementary file S1, online supplementary 
table S1, with references. Online supplementary file S1, 
online supplementary table S1 also lists the material used 
in control Arm 1. The standard material is essentially that 
used in common clinical practice60 and the short version 
a simplified version deliverable in practice during a short 
period of time. The packages include measurement 
instruments and patient advice material for comorbid 
depression implemented with patients with an AUDIT- C 
score of 8+. Online supplementary file S1, online supple-
mentary table S1 summarises the differences between the 
standard and short versions of the training programme.
The standard and short care pathways that are imple-
mented are summarised in online supplementary file S1, 
online supplementary figures S1 and S2.
Essentially, in all arms, PHC providers are asked to 
measure the alcohol consumption of all adult patients 
who consult for whatever reason using AUDIT- C. The 
three AUDIT- C questions are included in a paper tally 
sheet completed by the provider, in which the providers 
document the outcome of the consultation (advice 
given, patient referred, etc). The local researchers visit 
each PHCU on a 2–4 weekly basis to collect completed 
tally sheets and deliver new tally sheets as required. The 
local researchers collect information on the total number 
of adult patients (aged 18+ years) registered with each 
PHCU and the monthly number of total adult consul-
tations with each provider. Patients who score <8 with 
AUDIT- C are given a patient information leaflet. Patients 
who score 8+ with AUDIT- C are assessed and manged as 
appropriate for depression, and are advised to reduce 
their alcohol consumption, unless there are clinical indi-
cations for referral. Arm 4 differs from Arm 3 in having a 
lengthier assessment, if indicated, and a longer session of 
advice giving.
By Month 6, Hypothesis 3, that is, non- superiority of 
Arm 4 (standard package with municipal action and stan-
dard training) over Arm 3 (short package with municipal 
action and short training) will be tested. In the presence 
of clinical equivalence of a relative difference of the 
primary outcome, that is, the cumulative coverage of 
patients whose alcohol consumption is measured, of less 
than 10%, Arm 4 will be replaced by Arm 3 from month 
8 onwards, figure 3.
The municipal integration and support inputs to 
Arms 3 and 4 within the intervention municipal area 
are summarised in online supplementary file S1, online 
supplementary table S2, with references. Municipal inte-
gration and support comprises:
1. Creation of local CAB of local stakeholders to advise 
on tailoring of materials, support local implementa-
tion and review drivers of successful action.
2. Appointment of local project champion to advocate 
for successful implementation of programmes.
3. Implementation of five evidence- based adoption 
mechanisms.
4. Implementation of five evidence- based support sys-
tems.
5. Implementation of community- based communication 
campaigns.
Tailoring
The CABs and UPs review and tailor relevant mate-
rials of the clinical package and training courses and 
of the municipal integration and support inputs within 
the seven domains of: (1) local and national guideline 
factors; (2) individual healthcare provider factors; (3) 
patient factors; (4) interactions between different profes-
sional groups; (5) incentives and resources; (6) capacity 
for organisational change and (7) social, political and 
legal factors.62–64
The study timetable is summarised in figure 4. The 
data management plan, as submitted to the European 
Commission, is available as online supplementary file 
S2.
Figure 3 Study design from month 8 onwards, assuming no superiority of Arm 4 over Arm 3 during first 6 months of 
implementation. PHCU, primary healthcare units.
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Data collection and instruments
During set-up phase for Arms 1–4
 Municipal level information
At the level of the municipal area (or, when not available, 
at whole city, regional or country level), the following 
information will be collected from routinely available data 
on sociodemographic factors, alcohol and mental health 
data, health system structures, quality of life, sustainable 
governance and values, online supplementary file S1, 
online supplementary table S3.
PHCU and provider level information
All contacted PHCU, including those who did and did 
not agree to be part of the study, will provide information 
on the following:
 ► Numbers of registered patients, divided into age 0 to 
17 years and 18+ years.
 ► Numbers and professions of provider staff (including 
physicians, nurses, nurse technicians, midwifes, 
psychologists, social workers and others).
At recruitment, PHC providers will provide data on 
their:
 ► Age.
 ► Gender.
 ► Profession (doctor, nurse, practice assistant, etc).
 ► Time worked in the PHC.
 ► Data on their attitudes and experiences to working 
with patients with heavy drinking and comorbid 
depression (online supplementary file S1, online 
supplementary table S4).
Since we are unable to randomise the municipal 
areas involved, we will use propensity score matching 
(PSM) based on data collected at the level of the munic-
ipal area and the PHCU, to take into account potential 
confounding variables between control and intervention 
municipal areas, and minimise bias on account of these.
During 1-month baseline measurement period for Arms 1–4
Provider-based measurement and assessment of alcohol 
consumption and comorbid depression and record of advice and 
treatment given (tally sheets)
Based on the validated methodology of the ODHIN 
project,22 24 PHC providers will be asked to document 
activity by completing anonymous paper tally sheets 
that record eligible patients’ (aged 18+ years) AUDIT- C 
scores,65 and, if administered (as documented in online 
supplementary file S1, online supplementary table S1), 
AUDIT-10,66 Patient Health Questionnaire (mental disor-
ders), 2- item version (PHQ-2)67 and PHQ-968 scores, and 
the advice or treatment given to each patient. The tally 
sheets will record the age, sex and educational level of 
the patient, the latter as a proxy measure of socioeco-
nomic status. PHCUs will return data on the number 
of adult (aged 18+ years) consultations per provider for 
the 1- month baseline measurement period. Tally sheets 
will be delivered to the PHCU to be distributed to the 
Figure 4 Study timetable.
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participating providers at the beginning of the 1- month 
baseline measurement period and collected at the end of 
the period, with no other contact during the period.
During training prior to implementation for Arms 2–4
Providers will complete a short questionnaire after the 
initial training sessions. The questionnaires, which are 
adapted based on specific training contents (standard or 
short package), will assess the participants’ experience 
of the training, measuring satisfaction with the compo-
nents of the training aspects, as well as their perceived 
utility. Two measures included in the main provider ques-
tionnaires, Short Alcohol and Alcohol Problems Percep-
tion questionnaire (SAAPPQ)69 and self- efficacy,70 will 
be included in order to assess the specific impact of the 
training, independent of the effect of the implementa-
tion of the intervention.
During 18-month implementation period for Arms 1–4
Provider-based measurement and assessment of alcohol 
consumption and comorbid depression and record of advice and 
treatment given (tally sheets)
The same mechanism, for tally sheets used during the 
baseline measurement period will continue for each 
calendar month of the 18- month implementation period. 
Tally sheets will be delivered monthly to each PHCU 
to distribute to participating providers. Completed 
tally sheets will be collected at the end of each month. 
Following training in Arms 2–4, and municipal support in 
Arms 3–4, each provider determines use and completion 
of the tally sheets, with no additional prompting. Monthly 
data will be collected and reported with accumulation of 
coverage over time. Formal reporting will be undertaken 
at baseline, and for coverage achieved by month 12 and 
by month 18 of the 18 month implementation and test 
period. Tally sheets will include an identifying code of the 
provider, PHCU, country and study arm, but no identi-
fying code of the patient. Data will be extracted and sent 
to the project’s data warehouse at Technical University 
Dresden on a monthly basis.
Extended tally sheets
As part of quality control, in all four arms at two time 
points, during the 18- month implementation and test 
period (months 3 and 15), providers will complete 
extended tally sheets on two separate days in each month. 
The extended tally sheets will include an identifying code 
of the provider but no identifying code of the patient. The 
extended tally sheet will include additional information 
from the patient on alcohol knowledge,71 social norms72 
and health literacy73 applied to alcohol, as it informs the 
content of advice given; and, additional information from 
the provider on contextual characteristics that informed 
their advice giving. The extended tally sheets will include 
a consent form for the patient and self- completed addi-
tional questions for the patient to complete, once the 
consultation has ended.
Self-completed additional questions by patient
On two separate days, during months 3 and 13, coinciding 
with and following the consultation with the provider 
using the extended tally sheet, patients who are able 
to read and write will be invited to give consent to self- 
complete additional questions to the extended tally sheet 
in the waiting room before leaving the PHCU, handing 
the completed tally sheet and questions to a researcher 
in attendance. No patient identifying information will be 
included in the questionnaires. Six domains, serving as 
quality control, will be included:
1. AUDIT- C.65
2. PHQ-2.67
3. Experiences of the consultation.
4. Views on being asked about alcohol consumption.
5. Health literacy73 as it applies to alcohol.
6. Exposure to communication and media campaigns on 
alcohol.
On each day, 270 patient questionnaires will be 
collected across all PHCUs, with up to 1080 (540 during 
each of months 3 and 13) questionnaires completed in 
total across the 4 days.
Provider-based attitudes and experiences
At two time points during the 18- month implementation 
period (months 3 and 13), providers will provide data on 
their attitudes and experiences to working with patients 
with heavy drinking and comorbid depression, online 
supplementary file S1, online supplementary file S2.
Providers will complete a short questionnaire after each 
of the booster training sessions that they attended (at 
months 4 and 8). The specific content, number and timing 
of the training- related questionnaires will depend on the 
study arm: Arm 2 and 3 participants will fill in one question-
naire after the booster session; while Arm 4 participants will 
fill in two after each of the two booster sessions.
Observations
The training sessions with the PHC providers, and the 
meetings of the CABs will be observed by a neutral observer 
in order to take note of additional possible barriers in the 
implementation of the protocol that emerge through the 
training sessions and meetings. Participant responsive-
ness will also be observed.
Economic data for return-of-investment analyses
Within SCALA, we will conduct return- on- investment 
(RoI) analyses, by assessing for each EURO invested in 
scaling up delivery of screening and brief interventions in 
PHC in Columbia, Mexico and Peru, how many EUROs 
will be saved by reductions in future healthcare utilisa-
tion. The return of investment will be defined as the 
(return on investment=(gain from investment–cost of 
investment)/cost of investment). For details on the data 
required for RoI analyses, online supplementary file S1, 
online supplementary table S5.
For the RoI analyses, the effects of increased coverage of 
alcohol brief advice among PHC patients will be modelled 
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using effect sizes from previous meta- analyses.52 74 To 
translate the reduced intake of alcohol into health gains, 
we will calculate alcohol- attributable fractions for major 
disease and injury categories. These fractions will then be 
applied to the cost data outlined in online supplemen-
tary file S1, online supplementary table S5 to estimate the 
alcohol- attributable costs per disease category.
Process evaluation
As the intervention is embedded in a complex system 
involving actions and actors at different levels (individual, 
organisational and municipal), a thorough process evalu-
ation will be carried out to complement and better under-
stand the outcomes. Through the process evaluation, the 
implementation with its fidelity and adaptation will be 
assessed, along with the drivers of scale- up and contex-
tual factors influencing the implementation, the drivers 
and the outcomes. This will be achieved in four blocks: 
driver diagram creation; barriers and facilitators analysis; 
assessment of implementation, mechanisms of impact 
and context and further contextual and policy analysis.
Key informant interviews
A number of individual or group interviews will be under-
taken throughout the project with key stakeholders—pro-
viders, UP members, CAB members, municipal and 
PHC- based clinical leaders, project partners and any other 
people involved in the implementation of the SCALA 
project. Depending on the stakeholder and their involve-
ment in the project, the topics of the interviews will cover 
topics such as the necessary adaptation to the protocol; 
the experience of implementing the programme in PHC 
practice and the perception of the municipal support and 
the community campaigns.
Driver diagrams
Driver diagrams75 will be used in order to describe the 
intervention and its causal assumptions, providing the 
theory of change through displaying what contributes to 
intervention aim and what are the relationships between 
primary drivers, secondary drivers and specific change 
ideas/activities. The initial general driver diagram, online 
supplementary file S1, online supplementary figure S3, 
will be modified based on local contexts and adapted 
throughout the duration of the project in order to under-
stand how scale up varies in the different cities.
Barriers and facilitators assessment
Factors influencing the implementation of the SCALA 
protocol will be assessed before the implementation, as 
well as monitored throughout. The anticipated barriers 
and facilitators to implementation will be assessed 
through development of evaluation tool based on liter-
ature review76–78 and implementation framework,62 
with subsequent refinement and adaptation to the local 
context through focus group discussions and workshops 
with the CABs. The aim of the tool is to identify the 
barriers that would have to be addressed and monitored 
throughout implementation and the facilitators that 
would incentivise and engage providers and the primary 
healthcare unit (PHCU) managers in uptake and scaling 
up of the SCALA protocol. The experienced barriers and 
facilitators will be further monitored through meeting 
observations, provider questionnaires and interviews, as 
well as interviews with other involved stakeholders (eg, 
CAB members, PHCU managers).
Implementation, mechanisms of impact and context
The factors influencing the progress from scale- up to 
outcomes will be identified and documented based on UK 
Medical Research Council guidance,79 analysing factors 
within five groups: (1) description of intervention and its 
causal assumptions, (2) implementation, (3) mechanisms 
of impact, (4) context and (5) outcomes. All aspects of the 
intervention will be taken into consideration: the interven-
tion, intervention tailoring, training, training tailoring, as 
well as the municipal action, consisting of the CABs and the 
communication campaign, combining both quantitative 
and qualitative methods in order to obtain a comprehen-
sive picture of the integration and interaction of included 
variables. A detailed description of the topics of interest and 
accompanied methods is presented in online supplemen-
tary file S1, online supplementary table S6.
The five groups will be assessed as follows:
1. Description of the intervention. The description of the 
intervention and its causal assumptions draws from the 
previously described driver diagram.
2. Implementation. Delivery of the training will be as-
sessed though document analysis (reports from train-
ing), observation and self- reports from the trainers. 
Delivery of the intervention will be assessed through 
document analysis, interviews with patients and pro-
viders. The areas of focus will be fidelity, adaptation, 
dose and reach. Implementation of the CAB meetings 
and community action will be assessed mainly through 
document analysis, as well as key informant interviews.
3. Mechanisms of impact. The following three areas will 
be covered: participant responses to the intervention, 
mediators and unintended consequences. Mechanisms 
of impact of intervention delivery will be assessed 
through patient and providers’ questionnaires. The 
patient interviews will focus on their responsiveness to 
the intervention, specifically looking at perceived ac-
ceptability. In order to evaluate participants’ responses 
to the training, a post- training questionnaire examin-
ing satisfaction with the training and perceived utility 
of training sessions will be applied, triangulated with 
data from observation and trainers’ self- report. Addi-
tionally, providers’ self- efficacy will be tested as poten-
tial mechanism of impact that links the implementa-
tion to the outcomes. Mechanisms of impact of the 
CAB meetings and community action will be examined 
through key informant interviews and questionnaires. 
Specific focus will be placed on perceptions and mech-
anisms of actions of the communication campaign, ex-
amining its effect on attitudes and social norms of both 
providers and patients.
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4. Context. Contextual factors that should be considered 
in order to better understand the success of the inter-
vention will be assessed through meeting observation, 
document analysis and provider questionnaires, as well 
as stakeholder interviews, with the main focus primar-
ily on individual and organisational level characteris-
tics of the context. For the training evaluation, context 
will be assessed through observation and trainers’ self- 
report. Context of municipal level actions will be as-
sessed through key informant interviews. Additionally, 
contextual and policy factors on national and munici-
pal levels will be assessed as described below.
5. Outcomes. The data collected through process eval-
uation will be combined with the outcomes and pre-
sented within the Reach, Effectiveness, Adoption, 
Implementation and Maintenance framework,80–82 
evaluating SCALA’s impact across the dimensions of 
reach, effectiveness, adoption, implementation and 
maintenance.
Contextual and policy factors
Based on methodology of Ysa et al,83 contextual and policy 
factors on national and municipal level will be identified 
through document analysis and key informant interviews. 
The main variables considered for contextual analysis will 
be: (1) available data similar to that of the OECD better 
life initiative;84 (2) Sustainable Governance Indicators85 
and (3) World Values Survey data.86 For policy analysis, the 
information sought will be for a for alcohol policy- related 
strategies, action plans, legislation and evaluations, both on 
country and municipal levels. The existing contextual and 
policy factors will be mapped onto the test of the scale- up of 
the SCALA package to describe and identify those factors 
on national and municipal level that might influence going 
to full scale beyond the tested scalable units.
Outcomes
Primary outcome
The primary outcome will be the cumulative proportion of 
the number of adults (aged 18+ years) registered with the 
PHCU that have their alcohol consumption measured with 
a completed AUDIT- C instrument during the study period 
(coverage). The number of adults registered is provided by 
the administrative office of the PHCU and includes all adult 
patients covered by the PHCU, whether or not they consult 
during the 18- month implementation test period.
Secondary outcomes
 ► Proportion of consulting patients who have their 
alcohol consumption measured by AUDIT- C: calcu-
lated as the number of adults who have their alcohol 
consumption measured by AUDIT- C divided by the 
total number of adults who consult the PHCU during 
the same time period per participating provider and 
per PHCU.
 ► At risk population receiving advice and/or treatment 
for heavy drinking: calculated as the number of adults 
with an AUDIT- C score of 8+ who receive brief advice 
and/or referral for their heavy drinking divided by the 
total number of patients with an AUDIT- C score of 8+ 
per participating provider and per PHCU. Informa-
tion will also be collected on the number of patients 
with an AUDIT- C score of <8 who receive brief advice 
and/or treatment for their heavy drinking.
 ► Proportion of patients with AUDIT- C score of 8+ 
who receive assessment for depression: calculated as 
the number of consulting adults with an AUDIT- C 
score of 8+ who complete PHQ-2 divided by the total 
number of patients with an AUDIT- C score of 8+ per 
participating provider and per PHCU.
 ► At risk population receiving advice and/or treatment 
for comorbid depression: calculated as the number of 
adults with a PHQ-2 score of 3+ who receive a patient 
leaflet and/or referral for their depression divided by 
the total number of patients with a PHQ-2 score of 3+ 
per participating provider and per PHCU.
 ► Provider attitudes: attitudes of the participating 
providers will be measured by the SAAPPQ.65 The 
responses will be summed within the two scales of 
role security and therapeutic commitment. Individual 
missing values for any of the items in a domain will be 
assigned the mean value of the remaining items of the 
domain before summation.
Statistical tests of key hypotheses
Primary study goal
Multilevel regression analyses will be undertaken at 12 
months’ time of the implementation test period, using 
cumulative results at months 1 to 12, and at 18 months’ 
time using cumulative results months 1 to 18. Both anal-
yses will include covariates of country and results during 
baseline month, analysed at the levels of the PHCU by 
study arm, taking into consideration the hierarchical 
nature of the data. For any PHCU that drops out during 
the study, outcome values for subsequent measurement 
points will be set at the last value obtained.
Hypothesis 1
Municipal action leads to more sustainable coverage 
among PHCU that receive training. We will compare 
results on primary outcome after 18 months with 
results after 12 months between Arm 3 versus Arm 2 via 
regression.
Dependent variables:
 ► For each PHCU, cumulative results of months 1–18 
of number of patients whose alcohol consumption is 
measured with AUDIT- C per 1000 registered patients; 
and cumulative results of months 1–12 per 1000 regis-
tered patients.
Random effects:
 ► Country as random intercept (test for inclusion).
Independent variables:
 ► Proportion of consulting patients who have their 
alcohol consumption measured with a completed 
AUDIT- C instrument during the baseline measure-
ment month.
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 ► Condition:
 – Municipal action (yes vs no).
 ► Covariate:
 – Proportion of consulting patients who have their 
alcohol consumption measured with a completed 
AUDIT- C instrument during the baseline measure-
ment month.
It is postulated that coverage for Arm 3 will be signifi-
cantly higher than for Arm 2.
Hypothesis 2
Training leads to higher coverage than no training. For 
both months 1–12 and months 1–18, compare cumulative 
coverage as per primary outcome between Arms 1 and 2 
via multilevel regression analyses.
Dependent variable
 ► Cumulative results months 1–12, and cumulative 
results months 1–18 of number of patients whose 
alcohol consumption is measured with AUDIT- C per 
1000 registered patients with
PHCU.
Random effects:
 ► Country as random intercept (test for inclusion).
Independent variables:
 ► Condition:
 – Training (Arm 2 vs Arm 1).
 ► Covariate:
 – Proportion of consulting patients who have their 
alcohol consumption measured with a completed 
AUDIT- C instrument during the baseline measure-
ment month.
It is postulated that coverage for Arm 2 will be signifi-
cantly higher than for Arm 1.
Hypotheses 3
In the presence of municipal action, the short clinical 
package and short training do not lead to less coverage 
than the standard clinical package and standard training. 
In the presence of clinical equivalence of a relative differ-
ence of cumulative coverage of patients screened by less 
than 10% by month 6, the difference between Arm 3 (all 
15 PHCU across the three countries) and Arm 4 (all 12 
PHCU across the three countries) will be assessed with 
regression analyses. If Arm 4 is not superior to Arm 3, 
both arms will be collapsed into Arm 3 (shorter package) 
from month 8 onwards.
Dependent variable:
 ► Cumulative results months 1 to 6 per 1000 patients.
Random effects:
 ► Country as random intercept (test for inclusion).
Independent variables:
 ► Condition:
 – Length of clinical package (longer=Arm 4 vs short-
er=Arm 3).
 ► Covariate:
 – Proportion of consulting patients who have their 
alcohol consumption measured with a completed 
AUDIT- C instrument during the baseline measure-
ment month.
It is postulated that Arm 4 is not significantly superior 
to Arm 3.
Sample size calculations for main hypothesis
As the outcome of the primary study goal is predicted to 
be Arm 3>Arm 2>Arm 1, we compared both Arm 2>Arm 
1, and Arm 3>Arm 2.
Our power calculations are based on the following 
assumptions: given an average size of a PHCU of approxi-
mately 15 000 adults, with an average of 1500 new consul-
tations per month, we expect a cumulative coverage after 
12 months of 0.0325 of the registered adult population 
to have had their alcohol consumption measured in 
the control condition (Arm 1) (data extrapolated from 
month 3 and month 9 assessments of control group from 
ODHIN study;22 24 Anderson, personal communication). 
For the short clinical package and short training (Arm 
2), we expect this to increase to 0.075 (data extrapolated 
from month 3 and month 9 assessments of training group 
from ODHIN study;22 24 Anderson, personal communica-
tion). Although the WHO Phase IV study predicts an addi-
tional beneficial impact of municipal support,41 precise 
empirical data is not available—however, we consider an 
estimate for Arm 3, with municipal support, to be 0.15, a 
proportion that would need to be achieved to consider 
municipal support to be worthwhile. To detect the differ-
ence between Arm 2 and Arm 1, assuming a design effect 
of 15 PHCUs (clusters) across the three municipal areas 
in Arm 2, with 15 000 patients (items), and 12 PHCUs 
(clusters) in Arm 1, with 15 000 patients (items), with 
an ICC for PHCUs of 0.03 (data from ODHIN study;22 24 
Anderson, personal communication) we would have 82% 
power at a significance level of 5%.87 For the difference 
between Arm 3 and Arm 2 (15 PHCUs/clusters in each 
arm), we would have 96.5% power.
Patient and public involvement
Patients were not involved in the design of the study but 
are involved in the tailoring processes. Existing literature 
suggests that most patients find it acceptable for PHC 
providers to ask about their drinking using validated 
measurement instruments, and support the delivery 
of brief advice to those drinking above recommended 
levels.88–96 However, the majority of the evidence to date 
draws on research conducted in Europe, and thus the 
findings are potentially less transferable to Latin Amer-
ican populations. In order to ensure the design and 
content of the intervention package, including related 
outcome measures, are appropriate for implementation 
in the target SCALA sites, we work closely with patients 
in each city to tailor patient materials. Within the inter-
vention municipal areas in each of the three countries, 
UPs are created with representatives of patients from the 
PHC centres. As part of the tailoring process, people and 
patients within the UPs have the opportunity to comment 
on the materials and information designed for use by 
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patients. The results of the study will be disseminated 
directly to patients and the public through information 
made available via the PHCUs.
DISCUSSION
The study has several features worth mentioning. It:
1. Uses a theory- based approach62–64 to tailoring clini-
cal materials and training programmes, creating city- 
based CAB, and user- based UPs to ensure that tailoring 
matches user needs, municipal services97 and copro-
duction of health.98
2. Sets a higher cut- off score for AUDIT- C (8+) than is 
commonly used to trigger advice- giving, matching 
definitions of heavy drinking99 100 and similar to base-
line levels of alcohol consumption in PHC- based trials 
to reduce heavy drinking.52 We set the same cut- offs 
for men and women, based on epidemiological evi-
dence,101 and to minimise unintended consequences 
of using different cut- offs for men and women.102 We 
recognise the importance of comorbid depression by 
building in identification, management and referral 
mechanisms.57–59
3. Tests for non- superiority of implementing a standard 
measurement and 5 min brief advice intervention with 
6 hours of training, compared with implementing a 
shorter 1 min brief advice intervention with 3 hours of 
training, taking into account that brief advice is as ef-
fective and cost- effective as more extended advice or 
treatment in reducing heavy drinking55 103 104 and the 
need for very brief clinical and training programmes 
for time- constrained providers.
4. Tests the added value of embedding and implement-
ing PHC activity within municipal- based adoption 
mechanisms and support systems,40 and communica-
tion campaigns over and above training programmes 
solely directed to PHC providers.
5. Has a longer time frame (18 months) than is tradition-
ally used in implementation studies,105 106 to assess lon-
ger term impacts.
6. Gives considerable emphasis to process evaluation,79 
developing logic models to document the fidelity of all 
implementation strategies, and to identify, the drivers 
and barriers and facilitators to successful implementa-
tion and scale- up, and the political and economic con-
textual factors that might influence scale- up.
There are some limitations to the study design. A trial 
with random assignment of municipal areas is not feasible 
due to municipal- based political and technical considera-
tions. As we are unable to randomise the involved munic-
ipal areas, we adopt a quasiexperimental design,1 trying 
to optimise control municipal areas for confounding, 
and by using PSM. While full comparisons via randomisa-
tion, and thus establishment of causality, are not possible, 
together with the qualitative evaluation component of the 
study, we will be able to clearly identify the mechanisms 
which were crucial in leading to the outcomes. According 
to a recent seven- item checklist for classifying quasiexper-
imental studies for Cochrane reviews,107 our approach is, 
nevertheless, ranked as a strong design, online supple-
mentary table S7.
Although our focus on embedding PHC activity within 
supportive municipal actions is hypothesised to increase 
measurement and brief activity over and above that previ-
ously demonstrated, such an approach also brings risks. 
Municipal and national governments change; and, thus 
health priorities may change. Although our approach 
minimises the need for extra resources (and in some juris-
dictions, could be resource saving),19 it is not resource 
free. Funding constraints could limit future scale- up and 
sustainability.
We have based our protocol adopted on a model of 
transdisciplinary research to promote sustainability. Such 
a model identifies, structures, analyses and deals with 
specific problems in a way that grasps the complexity 
of problems;108 it takes into account the diversity of 
real- world and scientific perceptions of problems; and 
develops knowledge and practices that promote what is 
generally accepted to be the common good.109 As such, 
we include municipalities and health systems as stake-
holders to form explicitly orchestrated and managed 
ecosystems that cross- organisational boundaries. Munic-
ipal areas and health systems create an engagement plat-
form that provides the necessary environment, including 
people and resources, for sustainability.
ETHICS AND DISSEMINATION
This protocol outlines a quasiexperimental study1 to test 
the extent to which embedding PHC- based measurement 
and brief advice activity within supportive municipal action 
leads to improved scale- up of an intervention package, 
with more patients having their alcohol consumption 
measured, and with heavy drinkers receiving subsequent 
appropriate advice and treatment. It is not envisaged 
that there will be any substantial protocol modifications 
during the course of the study. Any modification to the 
protocol will be described in all scientific publications.
All participating PHCUs and participating PHC 
providers sign an informed consent form for partici-
pation with the country- based research team. Selected 
patients at two separate time points sign an informed 
consent form with the country- based research team to 
provide additional anonymised information following 
a consultation with a PHC provider. The consent forms 
are included within Annexe Data Management Plan. 
All data collection, processing, and sharing procedures 
will adhere to national and international laws including 
the General Data Protection Regulation (EU Regulation 
2016/679), as described within the Annexe Data Manage-
ment Plan.
All materials are publicly available on the project 
website: https://www. scalaproject. eu/. According to the 
SCALA data management plan, by default, all quantitative 
data sets generated in the course of the SCALA study will 
be made openly available through the UK Data Service 
on publication of the results (http://www. data- archive. ac. 
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uk/). Prior to publication, all data will be formatted to 
meet UK Data Service requirements.
Ministries of Health at municipal and country levels 
are represented in the CAB created in each interven-
tion municipality to facilitate scale- up at municipal and 
country levels, once the implementation strategy is vali-
dated. SCALA works closely with the Pan American 
Health Organization (PAHO), with the principal inves-
tigator form Mexico being a Collaborating Centre with 
PAHO, to facilitate scale- up at Latin American levels, 
once the implementation strategy is validated.
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